Can an antibacterial coating on surfaces in an intensive care unit (ICU) prevent methicillin-resistant Staphylococcus aureus (MRSA) acquisition in patients?

ISRCTN ISRCTN31972004
DOI https://doi.org/10.1186/ISRCTN31972004
Secondary identifying numbers N/A
Submission date
29/10/2018
Registration date
19/11/2018
Last edited
29/11/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Methicillin-resistant Staphylococcus aureus (MRSA) can cause serious disease that can be difficult to treat because the bacteria cannot be killed by commonly used antibiotics. Patients can acquire MRSA while in hospital and can carry it into the community without showing signs of infection. Surfaces in hospital can be made to contain or can be treated with substances that kill bacteria continuously. This might be an effective way of controlling the spread of MRSA in hospitals. This study aims to investigate whether applying an antibacterial coating to surfaces in an intensice care unit (ICU) could reduce acquisition of MRSA and other disease-causing bacteria in the patients.

Who can participate?
All patients admitted to the medical ICU of Bundang Jesaeng Hospital during the study period were included, except patients aged under 18 years and patients in hospital for less than 72 hours.

What does the study involve?
For the first 5 months of the trial, patients were treated as usual except that the inside of their nostrils were swabbed within 48 hours of ICU admission and at discharge from hospital. A titanium dioxide coating was then applied to surfaces and walls in the ICU that were regularly touched by people. For the next 5 months, patients were again treated as usual except that the inside of their nostrils were swabbed within 48 hours of ICU admission and at discharge from hospital. The swabs were cultured in a laboratory to check for disease-causing bacteria, including MRSA.

What are the possible benefits and risks of participating?:
After the antibacterial coating had been applied, the participants might have a lower risk of acquiring disease-causing bacteria from the hospital environment. Otherwise, they were treated as normal, so there was no additional risk.

Where is the study run from?
The study was performed at Bundang Jesaeng Hospital, a 630-bed secondary care teaching hospital in Gyeonggi-do, South Korea.

When is the study starting and how long is it expected to run for?
January 2016 to December 2017

Who is funding the study?
Bundang Jesaeng Hospital

Who is the main contact?
Su Jin Jeong
Department of Internal Medicine, Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
(Tel: +82-2-2228-1986; E-mail: JSJ@yuhs.ac.kr; Fax: +82-2-393-6884)

Contact information

Dr Su Jin Jeong
Public

Department of Internal Medicine
Yonsei University College of Medicine
50-1 Yonsei-ro
Seodaemun-gu
Seoul
03722
Korea, South

Phone +82-2-2228-1986
Email JSJ@yuhs.ac.kr

Study information

Study designObservational cohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEnvironmental disinfection with a photocatalyst antimicrobial coating as an adjunctive measure to control transmission of methicillin-resistant Staphylococcus aureus (MRSA) in patients in intensive care units (ICU): a prospective cohort study in a high-incidence setting
Study hypothesisWe sought to evaluate the usefulness of a photocatalyst to reduce the risk of MRSA transmission, by comparing MRSA acquisition rate and nosocomial infection rate before and after photocatalyst coating.
Ethics approval(s)Institutional Review Board of Bundang Jesaeng Hospital Health System Clinical Trials Center, 02/06/2016, Jesaeng Hospital - infection 16-01.
Since the study had minimal health risk and the study subjects were anonymized, the Institutional Review Board waived the requirement for written informed consent from the patients.
ConditionMethicillin-resistant Staphylococcus aureus (MRSA) infection
InterventionA titanium dioxide-based photocatalyst was coated on high touch surfaces and walls. 5 months of pre-intervention data were compared with 5 months of post-intervention data. The incidence rates of multidrug-resistant organism acquisition and the rates of hospital-acquired blood stream infection, pneumonia, urinary tract infection, and Clostridium difficile–associated diseases were compared using Cox proportional hazards regression analysis.
Intervention typeOther
Primary outcome measureMRSA acquisition assessed using culture results which were obtained from patients’ nares up to 48 hours after ICU admission and on discharge from ICU.
Secondary outcome measures1. Vancomycin-resistant Enterococcus spp. (VRE) acquisition assessed by reviewing culture results and medical records from admission until discharge from ICU
2. Multidrug-resistant Acinetobacter baumannii (MRAB) acquisition assessed by reviewing culture results and medical records from admission until discharge from ICU
3. Clostridium-difficile–associated disease (CDAD) acquisition assessed by reviewing culture results and medical records from admission until discharge from ICU
4. Hospital-acquired infections (HAI), including bloodstream infection, pneumonia, and urinary tract infection as defined by The Centers for Disease Control and Prevention, assessed by reviewing culture results and medical records from admission until discharge from ICU
Overall study start date01/01/2016
Overall study end date31/12/2017

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants341 and 280 patients during baseline and intervention periods
Total final enrolment621
Participant inclusion criteria1. Admitted to the medical intensive care unit during the study period.
Participant exclusion criteria1. Aged <18 years
2. Hospitalized <72 hours
Recruitment start date01/09/2016
Recruitment end date31/07/2017

Locations

Countries of recruitment

  • Korea, South

Study participating centre

Bundang Jaeseng hospital
180-2 Seohyeon-ro
Bundang-gu
Seongnam-si
Gyeonggi-do
Seongnam
463-774
Korea, South

Sponsor information

Bundang Jesaeng Hospital
Hospital/treatment centre

180-2 Seohyeon-ro
Bundang-gu
Seongnam-si
Gyeonggi-do
Seongnam
463-774
Korea, South

Phone +82-31-779-0000
Email webmaster@dmc.or.kr
Website http://www.dmc.or.kr/global/index.do?lang=en
ROR logo "ROR" https://ror.org/03z0bdc81

Funders

Funder type

Hospital/treatment centre

Bundang Jesaeng Hospital

No information available

Results and Publications

Intention to publish date30/06/2019
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe research findings will be published in high impact research journals and presented at international conferences.
IPD sharing planThe datasets generated during and analysed during the current study will be available upon request from Su Jin Jeong (JSJ@yuhs.ac.kr) immediately after publication of the results. All of the anonymised individual participant data collected during the trial will be available, along with the study protocol and statistical analysis. These data will be available to any applicant for any purpose for an indefinite period.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 03/12/2018 Yes No
Basic results 04/01/2018 04/01/2019 No No

Additional files

ISRCTN31972004_BasicResults_04Jan18.pdf
Uploaded 04/01/2019

Editorial Notes

29/11/2022: Total final enrolment added.
04/01/2019: The basic results of this trial have been uploaded as an additional file.
05/12/2018: Publication reference added.